Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WNT1 | P04628 | 12/20 | 0.68 |
| ▸ | TGFBR1 | P36897 | 5/20 | 0.66 |
| ▸ | CLK2 | P49760 | 7/20 | 0.60 |
| ▸ | CLK3 | P49761 | 6/20 | 0.60 |
| ▸ | DYRK1A | Q13627 | 6/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17568878 | 0.99 | WNT1 (0.69) | WNT1TGFBR1CLK2CLK3DYRK1A | |
| SCHEMBL17568867 | 0.98 | WNT1 (0.69) | WNT1TGFBR1CLK2CLK3DYRK1A | |
| SCHEMBL17555854 | 0.96 | WNT1 (0.68) | WNT1TGFBR1CLK2CLK3DYRK1A | |
| SCHEMBL17586894 | 0.94 | WNT1 (0.76) | WNT1TGFBR1CLK2CLK3DYRK1A | |
| SCHEMBL17583350 | 0.94 | WNT1 (0.77) | WNT1TGFBR1CLK2CLK3DYRK1A | |
| SCHEMBL17568884 | 0.93 | CLK2 (0.67) | WNT1TGFBR1CLK2CLK3DYRK1A | |
| SCHEMBL17586893 | 0.92 | WNT1 (0.75) | WNT1TGFBR1CLK2CLK3DYRK1A | |
| SCHEMBL17568891 | 0.92 | CLK2 (0.68) | WNT1TGFBR1CLK2CLK3DYRK1A | |
| SCHEMBL17568941 | 0.92 | WNT1 (0.66) | WNT1TGFBR1CLK2CLK3DYRK1A | |
| SCHEMBL17587225 | 0.92 | WNT1 (0.67) | WNT1TGFBR1CLK2CLK3DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10206929-B2 | 3-(1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine and therapeutic uses thereof | SAMUMED, LLC (US) | 2019-02-19 | — | — | US | claimed |
| US-20180325910-A1 | 3-(1H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-B]PYRIDINE AND THERAPEUTIC USES THEREOF | VICKERS-SPLICE CO-INVESTMENT LLC (KY) | 2018-11-15 | — | — | US | claimed |
| US-9889140-B2 | 3-(1H-imidazo[4,5-C]pyridin-2-yl)-1H-pyrazolo[3,4-B]pyridine and therapeutic uses thereof | SAMUMED, LLC (US) | 2018-02-13 | — | — | US | claimed |
| US-9493487-B2 | 3-(1H-imidazo[4,5-C]pyridin-2-YL)-1H-pyrazolo[3,4-B]pyridine and therapeutic uses thereof | SAMUMED, LLC (US) | 2016-11-15 | — | — | US | claimed |
| US-10206929-B2 | 3-(1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine and therapeutic uses thereof | SAMUMED, LLC (US) | 2019-02-19 | — | — | US | disclosed |
| US-9889140-B2 | 3-(1H-imidazo[4,5-C]pyridin-2-yl)-1H-pyrazolo[3,4-B]pyridine and therapeutic uses thereof | SAMUMED, LLC (US) | 2018-02-13 | — | — | US | disclosed |
| US-9889140-B2 | 3-(1H-imidazo[4,5-C]pyridin-2-yl)-1H-pyrazolo[3,4-B]pyridine and therapeutic uses thereof | SAMUMED, LLC (US) | 2018-02-13 | — | — | US | disclosed |
| US-20170224697-A1 | 3-(1H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-B]PYRIDINE AND THERAPEUTIC USES THEREOF | VICKERS-SPLICE CO-INVESTMENT LLC (KY) | 2017-08-10 | — | — | US | disclosed |
| US-20170224697-A1 | 3-(1H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-B]PYRIDINE AND THERAPEUTIC USES THEREOF | VICKERS-SPLICE CO-INVESTMENT LLC (KY) | 2017-08-10 | — | — | US | disclosed |
| US-9493487-B2 | 3-(1H-imidazo[4,5-C]pyridin-2-YL)-1H-pyrazolo[3,4-B]pyridine and therapeutic uses thereof | SAMUMED, LLC (US) | 2016-11-15 | — | — | US | disclosed |
| US-9493487-B2 | 3-(1H-imidazo[4,5-C]pyridin-2-YL)-1H-pyrazolo[3,4-B]pyridine and therapeutic uses thereof | SAMUMED, LLC (US) | 2016-11-15 | — | — | US | disclosed |
| US-20160068549-A1 | 3-(1H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-B]PYRIDINE AND THERAPEUTIC USES THEREOF | MED-PATHWAYS II LIMITED (VG) | 2016-03-10 | — | — | US | disclosed |
| US-20160068549-A1 | 3-(1H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-B]PYRIDINE AND THERAPEUTIC USES THEREOF | MED-PATHWAYS II LIMITED (VG) | 2016-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160068549-A1 | 3-(1H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-B]PYRIDINE AND THERAPEUTIC USES THEREOF | WNT1, WNT3, WNT3A | WNT1 1/4885TGFBR1 375/4885CLK2 2369/4885 |
| US-20170224697-A1 | 3-(1H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-B]PYRIDINE AND THERAPEUTIC USES THEREOF | WNT1, WNT3, WNT3A | WNT1 1/4885TGFBR1 375/4885CLK2 2369/4885 |
| US-20180325910-A1 | 3-(1H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-B]PYRIDINE AND THERAPEUTIC USES THEREOF | WNT1, WNT3, WNT3A | WNT1 1/4885TGFBR1 375/4885CLK2 2369/4885 |
| US-10206929-B2 | 3-(1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine and therapeutic uses thereof | WNT1, WNT3, WNT3A | WNT1 1/4885TGFBR1 375/4885CLK2 2369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.